Current issues in malignant pleural mesothelioma evaluation and management - Wikidata - awgldk - TriplyDB

Current issues in malignant pleural mesothelioma evaluation and management

Current issues in malignant pleural mesothelioma evaluation and management

http://www.wikidata.org/entity/Q28393560

about

Overview of treatment related complications in malignant pleural mesothelioma.BAP1, a tumor suppressor gene driving malignant mesothelioma.Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.Tremelimumab for the treatment of malignant mesothelioma.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

P2860

Q33871599-BE24E9E2-06B1-414C-BDDD-C6A03A5FE1FA Q33890512-DEE37E30-B776-47CF-A294-BE2BF9A33868 Q35602502-4463E88E-68BF-4FFD-9546-25B92C6DE9E7 Q38416306-20DF6F56-93AE-4B93-A924-64E90F092DE4 Q38631254-7073047A-184E-4740-8DCC-930ADC381D22 Q38984929-338F166A-9567-4F54-8940-55B402B06AC5 Q41593380-8C3E4BBC-8876-4F37-AEDB-3627F3572188

P2860

Current issues in malignant pleural mesothelioma evaluation and management

http://www.wikidata.org/entity/Q28393560

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Current issues in malignant pleural mesothelioma evaluation and management

@ast

Current issues in malignant pleural mesothelioma evaluation and management

@en

Current issues in malignant pleural mesothelioma evaluation and management

@nl

type

label

Current issues in malignant pleural mesothelioma evaluation and management

@ast

Current issues in malignant pleural mesothelioma evaluation and management

@en

Current issues in malignant pleural mesothelioma evaluation and management

@nl

prefLabel

Current issues in malignant pleural mesothelioma evaluation and management

@ast

Current issues in malignant pleural mesothelioma evaluation and management

@en

Current issues in malignant pleural mesothelioma evaluation and management

@nl

P1433

Q28393560-40210676-6177-49A8-BCFE-59599DD4B5BD

P1476

Q28393560-BB1C2842-6D28-4CBE-A3BC-4F273A36D5BD

P2093

Q28393560-41663494-7648-4E68-821F-2FD704F70720

Q28393560-CF589DFA-B554-4806-ACD7-880C152A861C

P2860

Q28393560-0410877F-1ADD-4CF6-BA86-6E12A093154A

Q28393560-04138A01-C848-42DB-ADF3-DEC1D9E5EE74

Q28393560-09F2E935-C3EA-41B0-B8B4-EE2B006C9226

Q28393560-0DD8293C-1B24-4A4D-A85E-EF261D8E3241

Q28393560-0E944086-C1B0-4D41-B331-88AF81A1B950

Q28393560-0EBF4898-CF87-4F7F-A0C1-ED14DA00FF74

Q28393560-0F070FA5-0E82-4522-A7D5-D1742B320A1C

Q28393560-1183EC02-52E2-46F0-9C61-D2E6B222C476

Q28393560-14EB79DC-3F79-41C1-BC2F-BB1038EAEA67

Q28393560-1556484A-DBAB-4AA4-AE6D-DB403164E667

P304

Q28393560-A2629A08-1961-430B-BEA8-3C8F607310A8

P31

Q28393560-3B7591D6-77B9-4800-A237-E3D805E7BC57

P356

Q28393560-CAB6A6AB-EF75-4BB3-BE80-373F7FCE64D3

P407

Q28393560-48A9E92B-36B0-4518-A638-0DCEFBD704C4

P433

Q28393560-295B90B6-99AD-4ED8-A1C2-0EC9F23A71B6

P478

Q28393560-A20B2A5C-DA14-409D-87B8-8B7142B22482

P577

Q28393560-32C51CF3-E634-469D-A683-6BC83B5761EA

P698

Q28393560-F64675AE-E98F-4087-9407-C99F7CCFD9CA

P932

Q28393560-C334952B-D7FE-4B7A-937F-A82C213A3A45

P356

THEONCOLOGIST.2014-0122

P1433

P1476

Current issues in malignant pleural mesothelioma evaluation and management

@en

P2093

James P Stevenson

http://www.w3.org/2001/XMLSchema#string

Jing Ai

http://www.w3.org/2001/XMLSchema#string

P2860

Residential proximity to naturally occurring asbestos and mesothelioma risk in California

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.

Germline BAP1 mutations predispose to malignant mesothelioma

Mesothelin targeted cancer immunotherapy

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

CTLA-4 blockade in tumor models: an overview of preclinical and translational research

Surgery in mesothelioma--where do we go after MARS?

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

P304

975-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2014-0122

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25061089

http://www.w3.org/2001/XMLSchema#string

P932

4153452

http://www.w3.org/2001/XMLSchema#string